Authors:
Monali Tayade, Sampada Kulkarni
Download free PDF
Vial Adaptors Market Size & Share 2026-2035
Report ID: GMI7296
|
Published Date: October 2026
|
Report Format: PDF/Excel/Dashboard/Platform
Explore Our Licensing Options:
Vial Adaptors Market
Get a free sample of this report
What are you hoping to find?
Your PDF is on its way. Tell us little about your research goal, and we'll help you find the most relevant market insights.
Vial Adaptors Market Size
The global vial adaptors market was valued at USD 1.10 billion in 2025, is estimated at USD 1.17 billion in 2026, and is projected to grow at a 6.5% CAGR (2026–2035) to USD 2.06 billion by 2035.
Vial Adaptors Market Key Takeaways
Market Leader: B. Braun Melsungen AG led with over 13% market share in 2025.
Leading Players: Top 5 players in this market include B. Braun Melsungen AG, Becton Dickinson and Company, Baxter International, West Pharmaceutical Services, ICU Medical, which collectively held a market share of 36% in 2025.
The vial adaptors market is being reshaped by a higher proportion of injectable biologics, oncology therapies, and other preparations that require controlled transfer from vial to delivery system. At approximately USD 5.30 per unit in 2025, the blended selling price reflects a mix of premium hazardous-drug handling systems and lower-cost conventional configurations. Demand is therefore influenced not only by the number of administrations, but also by the clinical setting, sterility protocol, and product specification required for each transfer event.
GMI Analyst View
Our discussions with hospital pharmacy directors, procurement executives, and supply chain managers across key markets indicate that the global vial adaptors market entered the current demand cycle from a base of USD 896 million in 2022, establishing the foundation for the sustained demand build-up driven by post-pandemic healthcare normalization, biosimilar volume expansion, and progressive CSTD compliance investment that defines the current market phase.
Vial Adaptors Market Trends, Growth Drivers & GMI Forecast Outlook
Growth is anchored in the intersection of injectable-drug complexity and hospital safety requirements. Oncology compounding, biologic administration, and formalized hazardous-drug protocols expand the addressable use case, while budget discipline and the movement of selected therapies into self-administered formats limit conversion speed in lower-acuity settings.
Key Drivers
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Oncology is the most consequential demand engine because therapy administration often requires pharmacy compounding, reconstitution, or controlled transfer before bedside use. Global parenteral medicines recorded an 11% five-year CAGR from 2019 to 2024, reflecting a broader shift toward injectable treatment modalities across oncology, immunology, and metabolic care [2]IQVIA. "Playing the Long Game: The Promise of Ultra Long-Acting Injectables." iqvia.com. For vial adaptor suppliers, this changes the addressable mix toward use cases where containment, dose accuracy, and workflow reliability carry greater clinical and procurement weight.
Compliance is a separate source of demand rather than merely a by-product of higher drug volumes. Hazardous-drug handling protocols make the vial connection point part of a documented safety workflow, encouraging hospitals to standardize device selection across compounding and administration. New hospital capacity in Asia Pacific and the Middle East also creates opportunities to embed closed-system transfer practices in newly commissioned oncology and critical-care units rather than requiring a retrofit of established processes.
Key Restraints
Evidence anchors use cited external data; demand implications and forecast conditions represent GMI analysis.
Hospital economics can delay adoption even when the clinical case for closed transfer is well understood. Procurement teams must balance consumable spending against pharmaceutical cost inflation, workforce expenses, and competing capital priorities. This favors suppliers that can demonstrate workflow value, secure group-purchasing access, or offer configurations that meet the safety requirement without imposing an outsized cost premium on community and public hospital customers.
The rise of home-based administration presents a more structural constraint. When therapies move into prefilled, subcutaneous, or self-administered formats, the institutional preparation step that drives adaptor use can disappear. At the same time, the products that remain in hospital channels are often clinically complex or hazardous, preserving a higher-value need for reliable containment and sterile transfer. Unresolved performance-standardization questions add friction because procurement teams may rely on incumbent validation, installed-base familiarity, and contract alignment when comparing competing platforms.
GMI Analyst View
We see a bifurcated market rather than a uniform adoption curve. Highly regulated oncology and hospital-pharmacy environments have a clear operational reason to invest in compliant transfer systems, whereas cost-sensitive providers require a more immediate procurement and workflow justification before converting from established practices.
Vial Adaptors Market Segment Analysis
By Product Type
Single-Use Vented
The single-use vented segment generated USD 385 million in 2025 and is projected to expand at an 8.2% CAGR (2026–2035). Its position reflects the importance of pressure equalization, contamination control, and single-use handling in oncology and hazardous-drug workflows. Vented designs are particularly suited to multi-dose and higher-complexity preparations where stable withdrawal conditions and a closed transfer pathway are integral to the pharmacy protocol.
Single-use non-vented vial adaptors are projected to reach USD 641 million by 2035 and accounted for 30.0% of market revenue in 2025. These products serve applications where containment and sterile transfer matter more than pressure management, including immediate reconstitution and transfer into infusion systems. Their demand base is supported by standard hospital pharmacy preparation activities and by the preference for disposable configurations in institutional infection-control programs.
Multi-Use Vented
Multi-use vented adaptors represented 20.0% of market revenue in 2025 and are expected to generate USD 372 million by 2035. Their continued relevance is concentrated in settings that permit repeated vial access under controlled protocols and in non-hazardous drug applications where the cost benefit of multi-use systems remains meaningful. However, wider use of single-use products in tightly regulated markets limits the relative opportunity for reusable formats.
Multi-Use Non-Vented
The multi-use non-vented segment generated USD 165 million in 2025 and is expected to grow at a 5.5% CAGR (2026–2035). This configuration remains important in resource-conscious facilities that prioritize economical access to standard injectable medicines. Its slower trajectory reflects pressure from both infection-control expectations and the growing availability of purpose-built single-use alternatives for regulated hazardous-drug environments.
By Size
20 mm
The 20 mm segment generated USD 605 million in 2025 and is forecast to grow at a 7.5% CAGR (2026–2035). This format aligns with widely used vial geometries for multi-dose injectable products and is embedded in oncology pharmacy and hospital compounding workflows. Its demand is reinforced by the broad installed base of medications packaged in this format and by the need for standardized accessory compatibility in high-throughput preparation areas.
13 mm
The 13 mm segment is projected to reach USD 620 million by 2035 and held 30.0% of market revenue in 2025. Smaller-format vial access is increasingly relevant for high-value, small-volume biologics, precision-oncology products, and specialty preparations. Suppliers that can support secure connections without compromising workflow ergonomics or drug compatibility are better positioned as these applications gain commercial scale.
Other Sizes
Other sizes accounted for 15.0% of market revenue in 2025 and are forecast to grow at a 6.4% CAGR (2026–2035). This category reflects the need for adaptable solutions across non-standard vial formats used in specialty pharmaceuticals, compounding, and advanced biologic applications. Product development is increasingly tied to specific drug-device interfaces rather than a single standardized hospital-accessory model.
By Material
Polycarbonate
Polycarbonate generated USD 440 million in 2025 and is expected to expand at a 7.0% CAGR (2026–2035). Its established role rests on rigidity, transparency, dimensional consistency, and familiarity in validated medical-device workflows. For manufacturers, the material remains a practical choice where visual inspection and stable mechanical performance are central to clinical acceptance.
Silicone
Silicone is projected to reach USD 558 million by 2035 and grow at an 8.2% CAGR (2026–2035). Its momentum is linked to sealing, flexibility, and chemical-compatibility requirements in higher-value CSTD configurations. The material is especially relevant where elastomeric interfaces must perform consistently with viscous biologics, hazardous therapies, or demanding extractables-and-leachables expectations.
Polyethylene
Polyethylene generated USD 220 million in 2025 and is projected to reach USD 413 million by 2035. Its commercial relevance comes from cost efficiency, chemical inertness, and compatibility with established sterilization processes. The material supports volume-oriented configurations and provides manufacturers with a viable route to serve price-sensitive institutional channels without abandoning core safety and handling requirements.
Other Materials
Other materials are expected to account for 14.0% of market revenue by 2035 and expand at a 6.4% CAGR (2026–2035). Specialty polymers, blends, and elastomeric combinations are being evaluated for applications where conventional materials do not fully address drug-contact, sterility, or device-integration requirements. This category is therefore closely connected to the emergence of bespoke biologic and cell-therapy preparation workflows.
By End Use
Hospitals
Hospitals generated USD 715 million in 2025 and are forecast to grow at a 6.9% CAGR (2026–2035). The hospital channel combines oncology infusion, inpatient pharmacy, critical care, and surgical drug-preparation needs, creating recurring consumption across multiple clinical departments. Compliance requirements make the category strategically important because product performance must fit established pharmacy procedures, training regimes, and audit expectations.
Ambulatory Surgical Centers
Ambulatory surgical centers are projected to reach USD 578 million by 2035 and expand at an 8.5% CAGR (2026–2035). Outpatient migration is moving a larger share of injectable care into settings that still require dependable medication preparation and hazardous-drug controls. These facilities often make concentrated procurement decisions, creating an opening for suppliers that can combine compliance assurance with operational simplicity and disciplined pricing.
Other End Use
Other end-use settings accounted for 10.0% of market revenue in 2025 and are projected to grow at a 6.0% CAGR (2026–2035). Specialty pharmacies, home-infusion providers, and compounding service centers create a varied demand base with different exposure to formal oversight. Adoption depends on whether the setting handles hazardous products, how preparation is centralized, and the degree to which payer and provider models favor decentralized delivery.
GMI Analyst View
We believe the market is moving away from a general-purpose accessory model toward more application-specific product selection. Material choice, vial geometry, and end-use protocol increasingly shape purchasing decisions, making clinical fit and validated workflow integration more important than a simple unit-cost comparison.
Vial Adaptors Market Regional Analysis
North America Vial Adaptors Market Analysis
The North America vial adaptors market generated USD 495 million in 2025 and is projected to reach USD 865 million by 2035. The region combines mature hospital infrastructure with stringent hazardous-drug handling practices and a large base of oncology infusion and specialty-pharmacy activity. Demand is reinforced by institutional requirements for validated, standardized products that can be integrated into established pharmacy and medication-administration workflows.
U.S.
The U.S. market generated USD 445 million in 2025 and is expected to grow at a 6.3% CAGR (2026–2035). Large hospital networks, oncology infusion volumes, and the interaction of compounding standards with accreditation processes sustain demand for closed-system-compatible vial adaptors. Supplier access depends heavily on formulary positioning, group-purchasing relationships, and clinical confidence in device performance.
Canada
Canada is projected to reach USD 94 million by 2035 and grow at a 7.3% CAGR (2026–2035). Provincial healthcare systems create relatively concentrated purchasing pathways, while public oncology and hospital-pharmacy programs support consistent demand. Growth is associated with broader integration of hazardous-drug handling practices across community facilities as well as specialist centers.
Europe Vial Adaptors Market Analysis
Europe is projected to generate USD 485 million by 2035 and expand at a 6.5% CAGR (2026–2035). The regional market benefits from developed hospital systems, a substantial injectable-medicine base, and growing institutional attention to occupational exposure during drug preparation. Adoption patterns vary among national procurement systems, making local regulatory knowledge and distributor capability important competitive differentiators.
Germany
Germany generated USD 55 million in 2025 and is projected to expand at a 6.2% CAGR (2026–2035). The country's extensive hospital and pharmacy infrastructure supports demand for dependable transfer solutions across oncology and immunology care. Structured quality expectations and a mature biosimilar market strengthen the rationale for standardized vial-access procedures.
France
France is expected to reach USD 67 million by 2035 and represented 13.8% of the European market in 2025. Centralized public procurement and regional hospital-group structures can accelerate adoption once a product secures an approved purchasing route. Demand is concentrated in oncology and hematology practice, where safety procedures are closely tied to institutional pharmacy operations.
UK
The UK generated USD 33 million in 2025 and is forecast to grow at a 6.8% CAGR (2026–2035). National Health Service procurement structures create a clear, though competitive, route to market for suppliers that meet clinical and economic requirements. Hazardous-drug handling expectations in hospital pharmacy continue to support the use of controlled transfer products.
Italy
Italy is projected to reach USD 47 million by 2035 and accounted for 10.2% of the European market in 2025. Demand is shaped by regional health authority procurement, oncology-service expansion, and the incorporation of occupational safety considerations into hospital pharmacy practice. Suppliers must navigate regional purchasing variation while demonstrating compatibility with local clinical workflows.
Spain
Spain generated USD 22 million in 2025 and is expected to expand at a 7.0% CAGR (2026–2035). Broader access to novel biologic therapies is increasing the need for reliable preparation practices within hospital oncology programs. Professional pharmacy guidance and formulary decision-making are supporting more consistent attention to closed-system transfer capabilities. Rest of Europe contributes further demand through a diverse mix of established Western European systems and gradually modernizing Central and Eastern European healthcare networks.
Asia Pacific Vial Adaptors Market Analysis
Asia Pacific is projected to reach USD 526 million by 2035 and grow at a 9.0% CAGR (2026–2035). The region's expansion is driven primarily by hospital build-out, rising access to oncology treatments, and a growing willingness among major institutional providers to adopt international drug-safety practices. Unlike mature markets, much of the opportunity comes from equipping new clinical capacity rather than replacing an existing installed base.
China
China generated USD 132 million in 2025 and is expected to grow at a 9.5% CAGR (2026–2035). Large tertiary hospitals and expanding oncology-treatment capacity are creating a sizable addressable base for closed-system transfer devices. Adoption is most pronounced where providers are formalizing pharmacy safety procedures and seeking more consistent preparation practices across high-volume clinical departments.
Japan
Japan is projected to generate USD 74 million by 2035 and expand at a 6.0% CAGR (2026–2035). The market is characterized by established quality expectations, sophisticated hospital pharmacy practice, and durable supplier relationships. Incremental demand is tied to oncology biosimilar use and the wider application of hazardous-drug protocols across medication categories.
India
India is projected to reach USD 88 million by 2035 and grow at an 11.5% CAGR (2026–2035). Healthcare-capacity investment, growing availability of injectable medicines, and the expansion of organized private hospital networks are broadening the market for safety-oriented pharmacy products. The most immediate opportunity is concentrated in metropolitan oncology centers and providers that are aligning procedures with international standards.
Australia
Australia represented 5.8% of the Asia Pacific market in 2025 and is expected to grow at a 7.0% CAGR (2026–2035). Concentrated state-based health networks and well-established pharmacy standards can support systematic product adoption once clinical and procurement criteria are met. This favors suppliers that can provide clear evidence packages and reliable national distribution.
South Korea
South Korea generated USD 11 million in 2025 and is projected to expand at an 8.0% CAGR (2026–2035). High urban hospital density, advanced pharmaceutical activity, and awareness of occupational exposure risks support demand for premium safety-oriented products. Market penetration is moving beyond leading academic centers as institutional purchasing standards develop. Rest of Asia Pacific contributes an emerging demand base as healthcare systems expand access to formal oncology and hospital-pharmacy services.
Latin America Vial Adaptors Market Analysis
Latin America generated USD 55 million in 2025 and is forecast to grow at a 7.5% CAGR (2026–2035). Demand is supported by wider oncology-treatment access and a gradual increase in institutional awareness of hazardous-drug safety. Adoption remains uneven because formal mandates and purchasing capability differ substantially between large private hospitals, public systems, and smaller regional providers.
Brazil
Brazil generated USD 28 million in 2025 and is expected to grow at a 7.8% CAGR (2026–2035). The country's large public hospital system offers substantial long-term volume potential, while private networks are more likely to adopt premium compliance-oriented configurations in the near term. Local distribution strength and pricing discipline remain important because demand spans both advanced and highly cost-sensitive procurement environments.
Mexico
Mexico is projected to reach USD 28 million by 2035 and expand at a 7.2% CAGR (2026–2035). Cross-border supply relationships and private-sector alignment with international safety practices support adoption in leading hospital systems. Public-sector opportunity is significant but requires products and commercial models that can withstand stringent price scrutiny. Rest of Latin America adds demand through expanding private oncology networks and infrastructure investment in major urban centers.
Middle East & Africa Vial Adaptors Market Analysis
The Middle East & Africa vial adaptors market generated USD 33 million in 2025 and is expected to grow at an 8.0% CAGR (2026–2035). Growth is closely linked to new hospital construction, specialty-care investment, and the incorporation of international pharmacy standards into newly commissioned facilities. The opportunity is therefore more investment-led than enforcement-led, with demand concentrated in advanced healthcare hubs.
Saudi Arabia
Saudi Arabia generated USD 11 million in 2025 and is projected to grow at an 8.5% CAGR (2026–2035). Healthcare-development programs and new oncology and specialty-care capacity are supporting demand for compliant medication-preparation products. Partnerships with international healthcare operators also raise the importance of products that align with widely recognized hospital safety protocols.
UAE
The UAE is projected to reach USD 15 million by 2035 and expand at a 9.0% CAGR (2026–2035). Private hospital investment, medical tourism, and the concentration of internationally accredited facilities encourage early adoption of advanced pharmacy safety systems. Suppliers benefit when their products can support premium clinical positioning without adding complexity to fast-moving hospital workflows.
South Africa
South Africa generated USD 7 million in 2025 and is expected to grow at a 7.0% CAGR (2026–2035). Private hospital groups are the principal channel for safety-compliant vial adaptor demand, while public procurement remains more price focused. The country provides an important regional base for suppliers seeking access to broader sub-Saharan healthcare markets. Rest of Middle East and Africa is supported by rising pharmaceutical access and selective investment in hospital infrastructure.
GMI Analyst View
We view regional growth as a set of distinct institutional adoption cycles. Mature markets are reinforcing established compliance systems, while faster-growing regions are incorporating drug-safety requirements as clinical infrastructure is built. This distinction will favor suppliers able to tailor commercial models and product configurations to local procurement maturity.
Vial Adaptors Market Share & Competitive Landscape
The vial adaptors market exhibits a moderately fragmented competitive structure, with B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Baxter International, West Pharmaceutical Services, and ICU Medical collectively accounting for approximately 36.0% of global market revenue in 2025. Market competition is influenced by product reliability, compatibility with drug preparation and administration workflows, regulatory compliance, and hospital procurement access. While standard vial-access products face competition from a broad range of regional and private-label suppliers, barriers to entry are higher in hazardous-drug handling and closed-system transfer applications, where clinical validation, safety performance, and established healthcare relationships play a critical role in supplier selection.
Other notable participants include CODAN Medizinische Geräte, Epic Medical, Helapet, Miltenyi Biotec, Thermo Fisher Scientific, VYGON, and Yukon Medical, which compete across standard vial-access products, aseptic pharmacy consumables, biologics preparation solutions, and cell therapy applications. As demand for medication safety and sterile drug handling continues to increase, competition is increasingly driven by product compatibility, safety performance, workflow integration, regulatory compliance, and the ability to support evolving pharmaceutical preparation requirements.
Recent Industry Developments
In May 2026, West Pharmaceutical Services updated its Vial Adapter transfer-device designs to align with ISO 80369-7 requirements for small-bore connectors used in intravascular and hypodermic applications [6]West Pharmaceutical Services. "Transitioning to ISO 80369-7: Enhancing Safety and Performance in Vial Adapter Transfer Devices." westpharma.com. The update affects connector design while preserving the vial-end interface and supports the company's position in procurement environments where current connector standards are increasingly important to product qualification.
In October 2025, Simplivia Healthcare received FDA 510(k) clearance for its Chemfort 28-day 20 mm Vial Adaptor and 13 mm Convertor [7]U.S. Food and Drug Administration. "510(k) Premarket Notification K253033 - Chemfort 28-Day 20 mm Vial Adaptor and 13 mm Convertor." accessdata.fda.gov. The clearance supports extended-use closed-system configurations for oncology pharmacy workflows and highlights continued product differentiation around microbial ingress protection and repeated vial access.
Need a specific section of this report?
Purchase regional analysis, country-level analysis, company profiles, or any other segment-level insights separately
based on your research needs.
Frequently Asked Questions (FAQs):
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Industry journals, trade publications, and specialized media.
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 20+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →